CoChat

Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia

Open access
Gentile, S., Turco, S., Guarino, G., Sasso, C. F., Amodio, M., Magliano, P., Salvatore, T., Corigliano, G., Agrusta, M., De Simone, G., Gaeta, I., Oliviero, B., Torella, R. · 2000 · Diabetes, Obesity and Metabolism
Cited by 66

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Summary: Although there is little information from primary or secondary prevention trials on cholesterol‐lowering medication in diabetic patients, the reduction of elevated cholesterol is widely recommended for this group. The American Diabetes Association (ADA) recommends drug therapy in diabetic patients if low density lipoprotein (LDL)‐cholesterol remains at > 130 mg/dl, or > 100 mg/dl in patients with macroangiopathy, after dietary intervention. When cholesterol‐lowering medication is indicated, the choice of the drug must take into account the other lipid abnormalities that are often present and the need to maintain optimal glycaemic control. In the present study we compared the efficacy and safety of the novel HMG‐CoA reductase inhibitor atorvastatin at the dose of 10 mg/day with simvastatin , lovastatin and pravastatin at doses of 10, 20 and 20 mg/day, respectively, and placebo, in type 2 diabetic patients with moderate elevation of LDL‐cholesterol with or without elevation of triglycerides. All the quoted agents are enzyme inhibitors effective in lowering LDL‐cholesterol in humans. The efficacy endpoints were the mean per cent changes in plasma LDL‐cholesterol (primary), total cholesterol, triglycerides, and high‐density lipoprotein (HDL)‐cholesterol concentrations from baseline to the end of treatment (24 weeks). Atorvastatin at a dose of 10 mg/day produced: (1) a significant reduction in LDL‐cholesterol (− 37%) in comparison with equivalent doses of simvastatin (− 26%), pravastatin (− 23%), lovastatin (− 21%), and placebo (− 1%); (2) HDL‐cholesterol increases (7.4%) comparable to or greater than those obtained with simvastatin (7.1%), pravastatin (3.2%), lovastatin (7.21%), and placebo (− 0.5%); (3) a significantly greater reduction in total cholesterol (− 29%) than that obtained with simvastatin (− 21%), pravastain (− 16%), lovastatin (− 18%), and placebo (1%); and (4) a significantly greater reduction in triglycerides than that obtained with all the other drugs and placebo. In all treatment groups no significant variation in fibrinogen concentration was observed. All reductase inhibitors studied had similar levels of tolerance. There were no incidents of persistent elevations of serum aminotransferases or myositis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1463-1326.2000.00106.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 66

Metadata

Authors
Gentile, S., Turco, S., Guarino, G., Sasso, C. F., Amodio, M., Magliano, P., Salvatore, T., Corigliano, G., Agrusta, M., De Simone, G., Gaeta, I., Oliviero, B., & Torella, R.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2000-12
Volume
2
Issue
6
Pages
355-362
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2111777372
Cited by
66
References
4
FWCI
3.41
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. https://app.cochat.ai/papers/10.1046/j.1463-1326.2000.00106.x
The paper
Gentile, S., Turco, S., Guarino, G., Sasso, C. F., Amodio, M., Magliano, P., Salvatore, T., Corigliano, G., Agrusta, M., De Simone, G., Gaeta, I., Oliviero, B., & Torella, R. (2000). Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. Diabetes, Obesity and Metabolism. https://doi.org/10.1046/j.1463-1326.2000.00106.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.